5WDF

Crystal structure of 10E8v4-5R+100cF Fab in complex with HIV-1 gp41 peptide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.1 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.247 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.

Kwon, Y.D.Chuang, G.Y.Zhang, B.Bailer, R.T.Doria-Rose, N.A.Gindin, T.S.Lin, B.Louder, M.K.McKee, K.O'Dell, S.Pegu, A.Schmidt, S.D.Asokan, M.Chen, X.Choe, M.Georgiev, I.S.Jin, V.Pancera, M.Rawi, R.Wang, K.Chaudhuri, R.Kueltzo, L.A.Manceva, S.D.Todd, J.P.Scorpio, D.G.Kim, M.Reinherz, E.L.Wagh, K.Korber, B.M.Connors, M.Shapiro, L.Mascola, J.R.Kwong, P.D.

(2018) Cell Rep 22: 1798-1809

  • DOI: 10.1016/j.celrep.2018.01.023

  • PubMed Abstract: 
  • Highly effective HIV-1-neutralizing antibodies could have utility in the prevention or treatment of HIV-1 infection. To improve the potency of 10E8, an antibody capable of near pan-HIV-1 neutralization, we engineered 10E8-surface mutants and screened ...

    Highly effective HIV-1-neutralizing antibodies could have utility in the prevention or treatment of HIV-1 infection. To improve the potency of 10E8, an antibody capable of near pan-HIV-1 neutralization, we engineered 10E8-surface mutants and screened for improved neutralization. Variants with the largest functional enhancements involved the addition of hydrophobic or positively charged residues, which were positioned to interact with viral membrane lipids or viral glycan-sialic acids, respectively. In both cases, the site of improvement was spatially separated from the region of antibody mediating molecular contact with the protein component of the antigen, thereby improving peripheral semi-specific interactions while maintaining unmodified dominant contacts responsible for broad recognition. The optimized 10E8 antibody, with mutations to phenylalanine and arginine, retained the extraordinary breadth of 10E8 but with ∼10-fold increased potency. We propose surface-matrix screening as a general method to improve antibodies, with improved semi-specific interactions between antibody and antigen enabling increased potency without compromising breadth.


    Organizational Affiliation

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
10E8v4-5R+100cF Fab heavy chain
H, A
232N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
FA10E8v4-5R+100cF FAB light chain
L, B
214N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
HIV-1 gp41 peptide
P, Q
17Human immunodeficiency virus type 1 group M subtype BMutation(s): 0 
Gene Names: env
Find proteins for P04578 (Human immunodeficiency virus type 1 group M subtype B)
Go to UniProtKB:  P04578
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.1 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.247 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 57.284α = 103.08
b = 60.953β = 107.46
c = 70.149γ = 100.05
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data scaling
PHASERphasing
HKL-2000data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-03-21
    Type: Initial release